These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36372942)

  • 1. Prescriber Adoption of SLCO1B1 Genotype-Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program.
    Obeng AO; Scott SA; Kaszemacher T; Ellis SB; Mejia A; Gomez A; Nadukuru R; Abul-Husn NS; Vega A; Waite E; Gottesman O; Cho J; Bottinger EP
    Clin Pharmacol Ther; 2023 Feb; 113(2):321-327. PubMed ID: 36372942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
    Vassy JL; Gaziano JM; Green RC; Ferguson RE; Advani S; Miller SJ; Chun S; Hage AK; Seo SJ; Majahalme N; MacMullen L; Zimolzak AJ; Brunette CA
    JAMA Netw Open; 2020 Dec; 3(12):e2027092. PubMed ID: 33270123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
    Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
    Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar.
    Tomcsanyi KM; Tran KA; Bates J; Cunningham FE; Silverman R; Norris AK; Moore VR; Voora D
    Am J Health Syst Pharm; 2023 Aug; 80(16):1082-1089. PubMed ID: 37210707
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Massmann A; Van Heukelom J; Green RC; Hajek C; Hickingbotham MR; Larson EA; Lu CY; Wu AC; Zoltick ES; Christensen KD; Schultz A
    Pharmacogenomics; 2023 May; 24(7):399-409. PubMed ID: 37232094
    [No Abstract]   [Full Text] [Related]  

  • 6. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating pharmacogenetic information and clinical decision support into the electronic health record.
    Goldspiel BR; Flegel WA; DiPatrizio G; Sissung T; Adams SD; Penzak SR; Biesecker LG; Fleisher TA; Patel JJ; Herion D; Figg WD; Lertora JJ; McKeeby JW
    J Am Med Inform Assoc; 2014; 21(3):522-8. PubMed ID: 24302286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men.
    Türkmen D; Masoli JAH; Kuo CL; Bowden J; Melzer D; Pilling LC
    Br J Clin Pharmacol; 2022 Jul; 88(7):3230-3240. PubMed ID: 35083771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
    Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
    Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    ; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
    N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-Consequence Analysis of Preemptive
    Brunette CA; Dong OM; Vassy JL; Danowski ME; Alexander N; Antwi AA; Christensen KD
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol.
    Bielinski SJ; Olson JE; Pathak J; Weinshilboum RM; Wang L; Lyke KJ; Ryu E; Targonski PV; Van Norstrand MD; Hathcock MA; Takahashi PY; McCormick JB; Johnson KJ; Maschke KJ; Rohrer Vitek CR; Ellingson MS; Wieben ED; Farrugia G; Morrisette JA; Kruckeberg KJ; Bruflat JK; Peterson LM; Blommel JH; Skierka JM; Ferber MJ; Black JL; Baudhuin LM; Klee EW; Ross JL; Veldhuizen TL; Schultz CG; Caraballo PJ; Freimuth RR; Chute CG; Kullo IJ
    Mayo Clin Proc; 2014 Jan; 89(1):25-33. PubMed ID: 24388019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
    Kaewboonlert N; Thitisopee W; Sirintronsopon W; Porntadavity S; Jeenduang N
    J Clin Pharm Ther; 2018 Oct; 43(5):647-655. PubMed ID: 29575099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
    Lu B; Sun L; Seraydarian M; Hoffmann TJ; Medina MW; Risch N; Iribarren C; Krauss RM; Oni-Orisan A
    Clin Pharmacol Ther; 2021 Sep; 110(3):733-740. PubMed ID: 34114646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and use of active clinical decision support for preemptive pharmacogenomics.
    Bell GC; Crews KR; Wilkinson MR; Haidar CE; Hicks JK; Baker DK; Kornegay NM; Yang W; Cross SJ; Howard SC; Freimuth RR; Evans WE; Broeckel U; Relling MV; Hoffman JM
    J Am Med Inform Assoc; 2014 Feb; 21(e1):e93-9. PubMed ID: 23978487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
    Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.